Daniel O'Day, Gilead CEO (AP Images)
February 3, 2023 06:19 AM EST
Pharma

Gilead boasts its best growth since 2015 de­spite plung­ing sales of Covid treat­ment

Katherine Lewin

News Reporter

Gilead sur­passed Wall Street and an­a­lyst ex­pec­ta­tions for Q4 earn­ings. Com­pa­ny lead­ers said Thurs­day that Gilead is in a cy­cle of in­vest­ment, tout­ing its launch …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times